Cipla's Hamied voices continued support for Indian compulsory licenses
This article was originally published in Scrip
Executive Summary
In the last few months Cipla has made moves to co-operate with global drug makers through product licensing deals, in a clear switch in the way the Indian firm wants to do business. But outspoken chairman Yusuf Hamied, the man who demolished the patent barriers of global drug makers, continues to see reasons for India to use interventions like compulsory licenses to facilitate drug access.